Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00277511
Other study ID # HR355/3036
Secondary ID
Status Completed
Phase Phase 3
First received January 13, 2006
Last updated October 11, 2007
Start date March 2003

Study information

Verified date October 2007
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

Primary objective:

- To investigate the microbiological efficacy, assessed as eradication rate based on microbiologically evaluable patients 1 month post treatment with oral Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category II)

Secondary objectives:

- To investigate the microbiological efficacy, assessed as eradication rate based on microbiologically evaluable patients 6 months post treatment with oral Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category II).

- To assess the clinical response rate based on resolution of signs and symptoms after 2 weeks of treatment; 5-12 days, 1 month, 3 months and 6 months post treatment with oral Levofloxacin 500 mg in male adults with chronic bacterial prostatitis (CBP, category II).

- To assess the safety of Levofloxacin 500 mg on the basis of adverse events, standard clinical chemistry, hematology, urinalysis and vital signs in male adults with chronic bacterial prostatitis (CBP, category II).


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

Subjects meeting all of the following criteria will be considered for enrollment into the study:

- A clinical diagnosis of chronic prostatitis as evidenced by the following criteria:

- clinical signs and symptoms of prostatitis and

- a history of chronic prostatitis as defined as: symptomatic prostatitis (a clinical diagnosis of prostatitis having been made for at least one previous episode which episode having lasted four weeks or two or more other episodes during the previous twelve months) and leucocyturia greater/equal 10 WBC/HPF x 400

- Laboratory evidence of prostatitis

- Candidate is appropriate for oral therapy.

- OTC medications for chronic prostatitis (other than antibiotics), which the subject has been receiving must continue throughout the study at the same dose or be discontinued prior to study entry.

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

- Need for parenteral therapy for the treatment of chronic bacterial prostatitis (CBP, Category II)

- Subjects with pathogen known or suspected to be resistant to the study drug

- Requirement for a second systemic antibacterial regimen

- Any condition which may interfere with the evaluation of the study drug including transurethral prostatectomy within 6 months of enrollment, the presence of a permanent transurethral catheter or a history of cystostomy or nephrostomy

- Taking medication that may effect bladder or prostate function (e.g. hormone therapy anticholinergics or alpha-blocker)

- Patients not receiving saw palmetto at the time of study entry should not start treatment with saw palmetto within 10 weeks of study entry

- Known prostatic carcinoma

- The presence of another infection requiring therapy with an antibacterial other than the study drug

- Greater than 24 hours of potentially effective therapy within seven days prior to study when there is documented evidence of a resistant organism or clinical failure after five or more days of previous antibacterial therapy

- History of hypersensitivity to the investigational product or to drugs with similar chemical structures

- History of tendonitis or tendon rupture

- Treatment with other quinolones in the last 14 days before study entry

- Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.

- Treatment with any investigational product in the last 30 days before study entry

- Clinically relevant cardiovascular, hepatic, neurologic, endocrine or other major systemic disease making implementation of the protocol or interpretation of the study results difficult

- History of drug or alcohol abuse

- Impaired hepatic function, as shown by:

- AST (SGOT) greater/equal 3 times the upper limit of the reference range

- ALT (SGPT) greater/equal 3 times the upper limit of the reference range

- bilirubin greater 51 µmol/l, i.e., greater 3 mg/dl (except of Gilbert disease)

- hepatic encephalopathy

- Impaired renal function, as shown by either creatinine clearance smaller 50 ml/min or undergoing hemodialysis or peritoneal dialysis (creatinine clearance may be estimated by formula or nomogram)

- Underweight (40 kg or less)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Levofloxacin


Locations

Country Name City State
Germany Sanofi-Aventis Berlin

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary efficacy data will be determined by eradication rate based on microbiologically evaluable subjects, evaluated for each pathogen and subject. determined at 1 month follow-up
Secondary Secondary efficacy data will be determined by microbiological eradication rate at 6 months follow-up
Secondary clinical response rate based on resolution of signs and symptoms after 2 weeks of treatment and during follow-up period.
See also
  Status Clinical Trial Phase
Completed NCT02246361 - Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Phase 4
Recruiting NCT00775515 - Laparoscopic Prostatectomy for Chronic Prostatitis Phase 2
Withdrawn NCT03027076 - Microbiome of Urologic Chronic Pelvic Pain Syndrome N/A
Completed NCT00402688 - An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis Phase 3
Suspended NCT00194636 - Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Phase 4
Recruiting NCT03720951 - Applying Pulsed Radiofrequency to the Pudendal Nerve Bilaterally Vs Its Application to Sacral Nerve Roots S2,3 and 4 Bilaterally in Chronic Prostatitis N/A
Completed NCT03879486 - Infectious Outcomes of Povidone-iodine Rectal Cleansing Plus Formalin Disinfection of Needle During Prostate Biopsy N/A
Completed NCT01676857 - Chemokine Mechanisms in Chronic Pelvic Pain
Completed NCT00236808 - A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis Phase 3
Completed NCT00169585 - Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA) Phase 3
Completed NCT01886547 - 2013 Annual National Digital Rectal Exam (DRE) Day Study N/A
Completed NCT00701311 - An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 2
Terminated NCT00194597 - Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Phase 4
Completed NCT03931538 - Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study N/A
Terminated NCT00529386 - Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Phase 1
Completed NCT00675298 - Linkage Analysis in Interstitial Cystitis N/A
Completed NCT00103402 - Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome Phase 3
Completed NCT00260637 - Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis Phase 2/Phase 3
Recruiting NCT01932645 - Etiology Study of Prostatitis
Completed NCT01826617 - Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome N/A